Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprenetapopt + Venetoclax + Azacitidine in TP53-Mutant AML
NCT04214860Phase 1Completed
- Sponsor
- Aprea Therapeutics
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eprenetapopt in acute myeloid leukemia (AML), sponsored by Aprea Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Complete Remission Rate. Started Dec 2019; status: completed.
02
Drugs
eprenetapopt
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04214860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214860.